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Tuberculosis (TB) is one of the oldest diseases known 
to  the  mankind;  it  is  also  a  leading  cause  of  death 
among adults, and kills almost 500 children each day 
worldwide. More than 90% of TB-related deaths occur 
in  developing  countries.  TB  was  declared  global 
emergency by the World Health Organization (WHO) 
in  1993,  with  around  8-10  million  new  cases  of  the 
disease  each  year  and  over  2-3  million  deaths 
worldwide (WHO Report, 2005). 
 
Nearly one third of the world’s population are latently 
infected  with  Mycobacterium  tuberculosis,  which 
produces  the  disease  in  immuno-compromised 
individuals,  such  as  those  with  HIV  infection. 
Consequently,  large  regions  of  sub-Saharan  Africa, 
Asia  and  Eastern  Europe,  where  HIV  is  prevalent 
and/or general populations have low immunity due to 
social  deprivation  and  poverty,  are  particularly 
vulnerable, and have seen a considerable rise in cases 
of TB during the past decade. TB cases have also been 
increasing in the USA and Western Europe since the 
1990s. This trend is likely fuelled by recent, increasing 
migration  of  populations  from  Eastern  European 
countries  to  Western  Europe.  After  years  of 
complacency  and  stagnation  recent  years  have  seen 
revitalization  of  the  TB  research,  recently  with  a 
particular  helping  from  Bill  and  Melinda  Gates 
Foundation. 
 
PROGRESS IN TB VACCINE DEVELOPMENT 
 
The Bacille-Calmette-Guérin (BCG) vaccine is health 
worker’s oldest weapon against TB, and is still the only 
commercially  available  TB  vaccine.  It  has  been 
successfully used to limit the disease in many countries 
through extensive neonatal immunisation programmes. 
However,  perhaps  due  to  genetic  differences  in 
different populations, environmental factors (e.g., high 
prevalence of environmental mycobacteria) or the type 
of  strain  used  in  vaccine  preparation,  BCG  vaccine 
affords  highly-variable  immune  protection  against 
pulmonary  TB  (see  Doherty  and  Anderson,  2005). 
BCG vaccine  protection  also  lasts only for 10  to  20 
years  (e.g.,  Sterne  et  al,  1998).  A  recent  study 
exploring revaccination of Brazilian children aged 7-14 
showed  that  it  did  not  provide  substantial  additional 
protection (Rodrigues et al, 2005), stressing the need 
for developing improved  vaccines. Currently, there are 
some  200  or  so  new  candidate  vaccines  in 
development. One such vaccine is being developed by 
Adrian Hill and colleagues at the University of Oxford, 
aiming to enhance the immunogenecity and protective 
efficacy of BCG (McShane et al, 2004), was recently 
granted  the  orphan  drug  status  by  the  European 
Commission  (Lang  et  al,  2005).  This  vaccine  is  a 
recombinant  modified  vaccinia  virus  Ankara 
expressing the antigen 85A gene from M. tuberculosis 
(MVA85A) and is currently in Phase 2 clinical trials in 
South Africa. Orphan drug status is generally granted 
for  rare  and  serious,  life-threatening  diseases  and 
where  the  drug  is  unlikely  to  generate  sufficient 
financial  returns  on  investment.  This  status  offers 
substantial incentives, including free scientific advice 
from  the  European  Agency  for  the  Evaluation  of 
Medicinal Products (EMEA) and an exclusive market 
in the EU for 6-10 years, and thus opens the door for 
the development of other medicines for diseases with 
poor expected financial returns. 
 
ADVANCES IN TB CHEMOTHERAPY 
 
Once an individual has been infected, the second line 
of resistance against TB is chemotherapy,  which has 
been clinically available for almost 60 years. However, 
more and more emerging strains of M. tuberculosis are 
resistant  to  currently  available  antimicrobial  drugs, 
further  weakening  our  defences.  While  treating  non-
resistant M.  tuberculosis  is challenging, resistance to 
antimicrobial drugs poses a further danger. 
 
Current  recommended  treatment  for  active  TB 
comprises  a  minimum  of  six  months  antibiotic 
treatment,  with  isoniazid  and  rifampicin  being  the 
front-line  agents  (others  include  ethambutol, 
streptomycin  and  pyrazinamide).  An  M.  tuberculosis 
strain  resistant  to  both  these  agents  is  termed 
multidrug- resistant (MDR), with or without resistance 
to other antimicrobials (Sharma and Mohan, 2006). A  
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recent report by the WHO and the International Union 
Against  Tuberculosis  and  Lung  Disease  (IUATLD) 
(WHO/IUATLD Report, 2004) suggests the prevalence 
of multidrug-resistant TB (MDR-TB) in participating 
countries  was  1.1%  for  new  cases  and  7%  for 
previously treated cases. MDR-TB requires treatment 
with  second  generation  antibiotics  that  are  less 
effective  and  more  toxic.  A  relatively  recent  and 
worrying development is the emergence of ‘extremely-
drug-  resistant  TB’  or  XDR-TB  (with  resistance  to 
three  or  more  of  the  six  classes  of  second-line 
antibiotics), with a fresh and the largest ever outbreak 
of XDR-TB reported in Kwa Zulu-Natal Province of 
South  Africa  (Cohen,  2006).  XDR-TB  has  been 
identified in almost all regions of the world with high 
prevalence in Asia and Eastern Europe. 
 
While several new TB vaccines are in the pipeline, the 
recent  upsurge  in  TB  research  has  also  attracted 
considerable  attention  in  the  arena  of  new  antibiotic 
development,  as  well  as  the  discovery  of  new  drug 
targets (Zhang et al, 2006). Andries et al (2005) have 
made  a  promising  new  development  in  the  front  of 
antibiotic  development,  and  have  identified  a 
diarylquinoline  (DARQ),  R207910,  that  potently 
inhibits  both  drug-sensitive  and  drug-resistant  M. 
tuberculosis in vitro (minimum inhibitory concentration 
0.06  mg/ml).  In  mice,  R207910  exceeded  the 
bactericidal  activities of  isoniazid and rifampin by at 
least  1  log  unit.  Other  promising  candidates  include 
new  fluoroquinolones,  rifamycin  derivative  (such  as 
rifapentine, rifabutin and rifalazil), oxazolidinones and 
nitoimidazopyran.  Even  some  anti-fungals  are  being 
considered  for  TB  therapy;  for  example,  azoles, 
phenothiazines  and  riminophenazine  derivatives  like 
clofazimine  show  good  anti-TB  activity  are  good 
candidates for further evaluation (Zhang et al, 2006). 
However, considering that no new antibiotic against TB 
has been introduced for almost past 40 years, and one of 
the most favourite drugs, R207910, is only in Phase 2 
clinical  trials,  it  may  be  some  time  before  we  see 
another new drug in the clinic. 
 
The immense global health and economic threat posed 
by TB and its resistance to drug enforces the need for 
ever  greater  and  concerted  global  efforts  to  develop 
new defences against this enemy. A failure to act now 
could cost heavily on future generations. 
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